Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.55
-0.07-4.32%
At close: -
$1.53
-0.02-1.29%
After Hours: 7:07 PM EDT
Comments
Loading...
Editas Medicine Analyst Ratings and Price Targets | NASDAQ:EDIT | Benzinga
Editas Medicine Inc has a consensus price target of $8.94 based on the ratings of 22 analysts. The high is $17 issued by Raymond James on June 13, 2023. The low is $3 issued by HC Wainwright & Co. on April 28, 2025. The 3 most-recent analyst ratings were released by Baird, HC Wainwright & Co., and Evercore ISI Group on May 13, 2025, April 28, 2025, and December 16, 2024, respectively. With an average price target of $4 between Baird, HC Wainwright & Co., and Evercore ISI Group, there's an implied 161.44% upside for Editas Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Evercore ISI Group
RBC Capital
Barclays
1calculated from analyst ratings
Analyst Ratings for Editas Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 161.44% | Baird | Joel Beatty67% | $8 → $4 | Maintains | Outperform | Get Alert |
| 04/28/2025 | Buy Now | 96.08% | HC Wainwright & Co. | Mitchell Kapoor38% | → $3 | Initiates | → Buy | Get Alert |
| 12/16/2024 | Buy Now | 226.8% | Evercore ISI Group | Liisa Bayko71% | $7 → $5 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | JP Morgan | Brian Cheng32% | — | Downgrade | Neutral → Underweight | Get Alert |
| 12/13/2024 | Buy Now | 161.44% | RBC Capital | Luca Issi43% | $5 → $4 | Maintains | Sector Perform | Get Alert |
| 12/13/2024 | Buy Now | 96.08% | Barclays | Gena Wang51% | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/13/2024 | Buy Now | — | Chardan Capital | Geulah Livshits47% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 422.88% | Baird | Joel Beatty67% | $10 → $8 | Maintains | Outperform | Get Alert |
| 12/13/2024 | Buy Now | 96.08% | Stifel | Dae Gon Ha49% | $11 → $3 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2024 | Buy Now | 161.44% | Wells Fargo | Yanan Zhu31% | $7 → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/05/2024 | Buy Now | 684.31% | Chardan Capital | Geulah Livshits47% | $12 → $12 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 226.8% | RBC Capital | Luca Issi43% | $8 → $5 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 618.95% | Stifel | Dae Gon Ha49% | $17 → $11 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 422.88% | Truist Securities | Joon Lee77% | $12 → $8 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 357.52% | Wells Fargo | Yanan Zhu31% | $9 → $7 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | 226.8% | Barclays | Gena Wang51% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 10/23/2024 | Buy Now | 96.08% | Evercore ISI Group | Liisa Bayko71% | $7 → $3 | Maintains | In-Line | Get Alert |
| 10/23/2024 | Buy Now | 488.24% | Wells Fargo | Yanan Zhu31% | $27 → $9 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 684.31% | Chardan Capital | Geulah Livshits47% | $20 → $12 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 422.88% | RBC Capital | Luca Issi43% | $8 → $8 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 749.67% | Jones Trading | Soumit Roy34% | → $13 | Initiates | → Buy | Get Alert |
| 08/08/2024 | Buy Now | 357.52% | Barclays | Gena Wang51% | $9 → $7 | Maintains | Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 684.31% | Truist Securities | Joon Lee77% | $20 → $12 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 880.39% | B of A Securities | Greg Harrison48% | $13 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 06/18/2024 | Buy Now | 684.31% | Oppenheimer | Jay Olson60% | $12 → $12 | Maintains | Perform | Get Alert |
| 05/30/2024 | Buy Now | 357.52% | Evercore ISI Group | Liisa Bayko71% | $15 → $7 | Maintains | In-Line | Get Alert |
| 05/09/2024 | Buy Now | 880.39% | Citigroup | Samantha Semenkow35% | $16 → $15 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 357.52% | Morgan Stanley | Matthew Harrison60% | → $7 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 488.24% | Barclays | Gena Wang51% | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 02/29/2024 | Buy Now | 945.75% | Citigroup | Samantha Semenkow35% | $11 → $16 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 618.95% | Barclays | Gena Wang51% | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 488.24% | JP Morgan | Brian Cheng32% | $8 → $9 | Maintains | Neutral | Get Alert |
| 12/12/2023 | Buy Now | 1207.19% | Truist Securities | Joon Lee77% | $15 → $20 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 618.95% | Citigroup | Samantha Semenkow35% | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 10/18/2023 | Buy Now | 422.88% | JP Morgan | Brian Cheng32% | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt34% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/29/2023 | Buy Now | 1011.11% | Stifel | Dae Gon Ha49% | $9 → $17 | Upgrade | Hold → Buy | Get Alert |
| 09/13/2023 | Buy Now | 815.03% | Cantor Fitzgerald | Rick Bienkowski27% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 815.03% | Cantor Fitzgerald | Rick Bienkowski27% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 684.31% | Oppenheimer | Jay Olson60% | → $12 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | Buy Now | 1141.83% | Chardan Capital | Geulah Livshits47% | $22 → $19 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 880.39% | Cantor Fitzgerald | Rick Bienkowski27% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | Buy Now | 1011.11% | Raymond James | Steven Seedhouse61% | → $17 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 684.31% | Oppenheimer | Jay Olson60% | → $12 | Reiterates | → Perform | Get Alert |
| 05/08/2023 | Buy Now | 422.88% | RBC Capital | Luca Issi43% | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 05/08/2023 | Buy Now | 815.03% | Credit Suisse | Richard Law47% | $15 → $14 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 1337.91% | Chardan Capital | Geulah Livshits47% | → $22 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 880.39% | Credit Suisse | Richard Law47% | $13 → $15 | Maintains | Neutral | Get Alert |
| 02/23/2023 | Buy Now | 1337.91% | Chardan Capital | Geulah Livshits47% | $35 → $22 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 553.59% | RBC Capital | Luca Issi43% | $14 → $10 | Maintains | Sector Perform | Get Alert |
| 02/01/2023 | Buy Now | 880.39% | Cantor Fitzgerald | Rick Bienkowski27% | → $15 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 357.52% | Morgan Stanley | Matthew Harrison60% | $8 → $7 | Maintains | Underweight | Get Alert |
| 01/23/2023 | Buy Now | 357.52% | SVB Leerink | Mani Foroohar47% | $6 → $7 | Maintains | Market Perform | Get Alert |
| 01/10/2023 | Buy Now | 292.16% | SVB Leerink | Mani Foroohar47% | $7 → $6 | Maintains | Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 2252.94% | Wells Fargo | Yanan Zhu31% | $50 → $36 | Maintains | Overweight | Get Alert |
| 12/13/2022 | Buy Now | 618.95% | Citigroup | Samantha Semenkow35% | → $11 | Initiates | → Neutral | Get Alert |
| 12/06/2022 | Buy Now | 749.67% | Credit Suisse | Richard Law47% | → $13 | Assumes | → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 880.39% | B of A Securities | Greg Harrison48% | $18 → $15 | Maintains | Neutral | Get Alert |
| 11/18/2022 | Buy Now | 2187.58% | Truist Securities | Joon Lee77% | $80 → $35 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 1076.47% | Baird | Joel Beatty67% | $25 → $18 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | 422.88% | Morgan Stanley | Matthew Harrison60% | $10 → $8 | Maintains | Underweight | Get Alert |
| 11/18/2022 | Buy Now | 815.03% | RBC Capital | Luca Issi43% | $32 → $14 | Maintains | Sector Perform | Get Alert |
| 11/18/2022 | Buy Now | 684.31% | Oppenheimer | Jay Olson60% | $28 → $12 | Downgrade | Outperform → Perform | Get Alert |
| 11/18/2022 | Buy Now | 749.67% | Credit Suisse | Tiago Fauth45% | $25 → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 2187.58% | Chardan Capital | Geulah Livshits47% | $43 → $35 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 357.52% | SVB Leerink | Mani Foroohar47% | $14 → $7 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 553.59% | Morgan Stanley | Matthew Harrison60% | $15 → $10 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | 1991.5% | RBC Capital | Luca Issi43% | $40 → $32 | Maintains | Sector Perform | Get Alert |
| 11/03/2022 | Buy Now | 1533.99% | Baird | Joel Beatty67% | $30 → $25 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 2710.46% | Chardan Capital | Geulah Livshits47% | $60 → $43 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 684.31% | SVB Leerink | Mani Foroohar47% | $14 → $12 | Maintains | Market Perform | Get Alert |
| 09/29/2022 | Buy Now | 1076.47% | B of A Securities | Greg Harrison48% | → $18 | Initiates | → Neutral | Get Alert |
| 08/04/2022 | Buy Now | 1011.11% | Barclays | Gena Wang51% | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 05/24/2022 | Buy Now | 422.88% | Goldman Sachs | Madhu Kumar72% | $10 → $8 | Maintains | Sell | Get Alert |
FAQ
What is the target price for Editas Medicine (EDIT) stock?
The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by Baird on May 13, 2025. The analyst firm set a price target for $4.00 expecting EDIT to rise to within 12 months (a possible 161.44% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ:EDIT) was provided by Baird, and Editas Medicine maintained their outperform rating.
When was the last upgrade for Editas Medicine (EDIT)?
The last upgrade for Editas Medicine Inc happened on August 8, 2024 when B of A Securities raised their price target to $15. B of A Securities previously had a neutral for Editas Medicine Inc.
When was the last downgrade for Editas Medicine (EDIT)?
The last downgrade for Editas Medicine Inc happened on December 16, 2024 when JP Morgan changed their price target from N/A to N/A for Editas Medicine Inc.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a maintained with a price target of $8.00 to $4.00. The current price Editas Medicine (EDIT) is trading at is $1.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
